Alembic Pharmaceuticals Limited
Tata AIA Life Insurance reduced its stake in Alembic Pharmaceuticals from 1.81% to 1.15%, selling 1,293,923 shares worth approximately ₹107.54 crore at ₹831.05 apiece.
A pharmaceutical company engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients for domestic and international markets. Alembic Pharma operates three dedicated research and development centers alongside five manufacturing facilities to support its operations across multiple therapeutic areas. The company focuses on producing generic and specialized pharmaceutical products while maintaining vertically integrated operations.
Joint venture between Tata Sons and AIA Group. AUM crossed Rs 1.3 lakh crore in May 2025, growing 27% YoY, making it one of the fastest-growing equity-oriented insurers in India. CIO Harshad Patil has run the investment book since 2014. Flagship Multi Cap Fund delivered 31.4% CAGR over 5 years, among the strongest performance in the ULIP universe.